ORTHOFIX MEDICAL INC.
OFIX Healthcare Medical Devices
ORTHOFIX MEDICAL INC.’s revenue for fiscal 2025 (year ended December 2025) was $822.3 million, up 2.85% from fiscal 2024. In the quarter to June 2026, revenue grew 3.85%, EPS fell 8.33%, free cash flow fell 516.6% and total debt rose 34.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow OFIX
ORTHOFIX MEDICAL INC. (OFIX) EV/Sales
As of 16 October 2026, ORTHOFIX MEDICAL INC. (OFIX) trades at a EV/Sales of 0.6×. Over the past ten years it has ranged from 0.6× (October 2022) to 2.6× (February 2019); the current reading is higher than 2% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.8× | (11.11%) |
| FY2024 | 1.0× | 27.54% |
| FY2023 | 0.7× | (13.80%) |
| FY2022 | 0.9× | (26.68%) |
| FY2021 | 1.2× | (36.50%) |
| FY2020 | 1.9× | 3.66% |
| FY2019 | 1.8× | (11.49%) |
| FY2018 | 2.0× | (5.11%) |
| FY2017 | 2.1× | 43.37% |
| FY2016 | 1.5× | (14.77%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.6× | (13.39%) |
| Mar 2026 | 0.7× | (16.45%) |
| Dec 2025 | 0.8× | (0.66%) |
| Sep 2025 | 0.9× | 24.75% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OFIX ORTHOFIX MEDICAL INC. | 0.6× |
| VMD Viemed Healthcare, Inc. compare | 1.2× |
| RCEL Avita Medical Inc. compare | 1.3× |
| CERS Cerus Corporation compare | 1.8× |
| BWAY Brainsway Ltd. Sponsored ADR compare | 2.6× |
| NPCE NeuroPace, Inc. compare | 4.2× |
| SI Shoulder Innovations, Inc. compare | 4.8× |
| SENS Senseonics Holdings, Inc. compare | 8.1× |
| CV CapsoVision, Inc. compare | 22.8× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)